JP6557253B2 - 抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用 - Google Patents

抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用 Download PDF

Info

Publication number
JP6557253B2
JP6557253B2 JP2016560467A JP2016560467A JP6557253B2 JP 6557253 B2 JP6557253 B2 JP 6557253B2 JP 2016560467 A JP2016560467 A JP 2016560467A JP 2016560467 A JP2016560467 A JP 2016560467A JP 6557253 B2 JP6557253 B2 JP 6557253B2
Authority
JP
Japan
Prior art keywords
cancer
compound
salt
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016560467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509672A (ja
JP2017509672A5 (enExample
Inventor
ウィリアム・ホーキンス
ロバート・マーク
ダーク・スピッツァー
スワンナ・バンベラボン
ブライアン・バン・タイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2017509672A publication Critical patent/JP2017509672A/ja
Publication of JP2017509672A5 publication Critical patent/JP2017509672A5/ja
Application granted granted Critical
Publication of JP6557253B2 publication Critical patent/JP6557253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016560467A 2014-04-01 2015-04-01 抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用 Active JP6557253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973366P 2014-04-01 2014-04-01
US61/973,366 2014-04-01
PCT/US2015/023954 WO2015153814A1 (en) 2014-04-01 2015-04-01 Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Publications (3)

Publication Number Publication Date
JP2017509672A JP2017509672A (ja) 2017-04-06
JP2017509672A5 JP2017509672A5 (enExample) 2018-01-25
JP6557253B2 true JP6557253B2 (ja) 2019-08-07

Family

ID=54241267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560467A Active JP6557253B2 (ja) 2014-04-01 2015-04-01 抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用

Country Status (8)

Country Link
US (5) US10087175B2 (enExample)
EP (1) EP3126356B1 (enExample)
JP (1) JP6557253B2 (enExample)
CN (1) CN106459011B (enExample)
AU (2) AU2015240775B2 (enExample)
CA (1) CA2944069C (enExample)
ES (1) ES2743701T3 (enExample)
WO (1) WO2015153814A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3126356B1 (en) 2014-04-01 2019-07-31 Washington University Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US11175296B2 (en) 2016-10-26 2021-11-16 Washington University Methods of diagnosing and treating cancer comprising ME1
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
EP1848698B1 (en) * 2005-01-25 2013-03-13 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
JP2008537726A (ja) * 2005-01-25 2008-09-25 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 癌細胞を殺傷するためのエラスチンアナログおよびその使用
WO2006130426A2 (en) 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
AU2006330883A1 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
WO2008013987A2 (en) * 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
US8324251B2 (en) * 2006-10-04 2012-12-04 Bristol-Myers Squibb Company Cyclic modulators of chemokine receptor activity
US8143222B2 (en) 2007-10-22 2012-03-27 Washington University Modular platform for targeted therapeutic delivery
EP3126356B1 (en) 2014-04-01 2019-07-31 Washington University Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Also Published As

Publication number Publication date
CN106459011B (zh) 2019-11-15
US10975069B2 (en) 2021-04-13
JP2017509672A (ja) 2017-04-06
US10087175B2 (en) 2018-10-02
WO2015153814A1 (en) 2015-10-08
US20190002457A1 (en) 2019-01-03
AU2015240775A1 (en) 2016-10-20
US20250145617A1 (en) 2025-05-08
EP3126356A1 (en) 2017-02-08
EP3126356B1 (en) 2019-07-31
AU2015240775B2 (en) 2019-01-03
ES2743701T3 (es) 2020-02-20
US20170015660A1 (en) 2017-01-19
EP3126356A4 (en) 2017-08-16
CA2944069C (en) 2022-03-08
US20200123149A1 (en) 2020-04-23
US10344029B2 (en) 2019-07-09
AU2019200353A1 (en) 2019-02-07
CN106459011A (zh) 2017-02-22
AU2019200353B2 (en) 2020-01-30
NZ724819A (en) 2020-09-25
CN106459011A8 (zh) 2017-06-30
CA2944069A1 (en) 2015-10-08
US20210221805A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US20250145617A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
ES2952281T3 (es) Compuestos deuterados para uso en el tratamiento del cáncer
US9296687B2 (en) Modulators of HSP70/DnaK function and methods of use thereof
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
JP7475062B2 (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
KR20230049678A (ko) 이카로스 또는 아이올로스에 의해 매개되는 장애를 위한 유리한 요법
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
WO2018005533A1 (en) Antiproliferative pyrimidine-based compounds
JP2015536986A (ja) 併用療法
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
KR101693326B1 (ko) 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 복합제
US20240374737A1 (en) Erk5 degraders and uses thereof
WO2018237190A1 (en) Pyridopyrazine compounds and uses thereof
NZ724963A (en) Mdm2 inhibitors and therapeutic methods using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190711

R150 Certificate of patent or registration of utility model

Ref document number: 6557253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250